Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort studyArticle Published on 2022-09-162022-11-15 Journal: Vaccine [Category] SARS, 진단, [키워드] administration Adverse reaction All participant anti-SARS-CoV-2 approved BBIBP-CorV can be used China Complete control group COVID-19 COVID-19 vaccine Cytopathic effect dose doses first dose geometric mean concentration geometric mean titer GMCs GMTs healthy immune persistence immunogenicity Immunoglobulin inactivated Inactivated vaccine Mild mitigate moderate NAb National not different not significantly different observation Observational cohort study Pragmatic regimens replacement Replacement vaccine Safety safety profile Safety. SARS-CoV-2 strain second dose sera severity Standard subject vaccination WHO [DOI] 10.1016/j.vaccine.2022.08.037 PMC 바로가기
Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccinationArticle Published on 2022-09-092022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] age analyzed anti-SARS-CoV-2 antibody BBIBP-CorV blood sample booster dose booster doses change Chi-square China convalescent convalescent sera CoronaVac COVID-19 COVID-19 vaccine cross-sectional Cytopathic effect dose enrolled evaluated Factor Factors FIVE geometric mean concentration geometric mean titer GMC GMT immune immune persistence immunogenicity Immunoglobulin inactivated individual influencing factors. linear models Logistic regression NAb neutralizing antibody NIBSC nine number ranged real-world data recipient recipients sample sizes SARS-CoV-2 SARS-CoV-2 strain seropositive Seropositivity Sex Standard subject understanding vaccination Vaccine Vaccines Vero Cell were measured WHO Zhejiang [DOI] 10.3389/fimmu.2022.967051 PMC 바로가기
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial중국 성인에서 SARS-CoV-2 BNT162b1 mRNA 백신 접종 후 면역 지속성 및 안전성: 무작위, 위약 대조, 이중 맹검 1상 시험Clinical Trial Published on 2022-08-012022-09-12 Journal: Advances in therapy [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Administered Antibody titer BNT162b1 candidate vaccine Chinese COVID declined dose geometric mean titer GMT GMTs immune persistence maintain mRNA mRNA vaccine mRNA vaccine. NAb neutralizing antibody nucleoside-modified mRNA Older participant Participants persistence Phase 1 Registered reported Safety safety profile SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Event the vaccine vaccination vaccination schedule Vaccine was determined [DOI] 10.1007/s12325-022-02206-1 PMC 바로가기 [Article Type] Clinical Trial
Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccineMVA-MERS-S 백신으로 후기 3차 면역 후 MERS-CoV-스파이크 특이적 B 세포 및 항체의 지속성Article Published on 2022-07-192022-09-11 Journal: Cell Reports Medicine [Category] MERS, 임상, 진단, [키워드] Administered antibody antibody isotypes B cell B cell response B cells binding boost booster booster vaccination caused coronavirus Coronavirus 2019 COVID-19 Cytometry ELISA ELISPOT ENhance enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay enzyme-linked immunospot flow cytometry Frequency highlight homologous IgG IgG ELISpot IgG subclasses IgG1 immune immune persistence immune response immune responses Immunity immunization Immunoglobulin ImmunoSpot increase isotypes late booster vaccination long-term immunity longitudinal analysis memory B memory B cells MERS MERS coronavirus MERS-CoV MERS-S Middle East Middle East respiratory syndrome modified vaccinia virus MVA-MERS-S neutralization capacity neutralization test Neutralizing Neutralizing antibodies neutralizing antibody persistence Phase 1 phase 1 trial plaque-reduction neutralization test PRNT50 Protein respiratory Respiratory disease significantly Spike protein syndrome T and B cell responses T cell T cell responses Vaccination strategies Vaccine Viral Viral vector vaccine viral vector vaccine. [DOI] 10.1016/j.xcrm.2022.100685 PMC 바로가기 [Article Type] Article
Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19COVID-19에 대한 CoronaVac 백신 접종 후 12개월 이내에 체액 및 세포 면역 반응의 상태Article Published on 2022-06-282022-09-11 Journal: mBio [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] 12 months addition antibody approved baseline binding binding and neutralizing antibodies binding antibodies binding antibody CD4 CD8 Cell Cellular immune response cellular response Cellular responses central memory CoronaVac country COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines Critical declined detectable dose effector memory Emergency use Endpoint enrolled Evidence functional gamma interferon granzyme B GzmB humoral Humoral and cellular immune responses IFN-γ IL-2 IL-5 immune memory immune persistence immune responses Inactivated vaccine interleukin interleukin 2 memory T cell memory T cells Month Neutralizing antibodies neutralizing antibody neutralizing antibody responses neutralizing antibody. participant persistence produced provide RBD Receptor-binding domain reported response SARS-CoV-2 SARS-CoV-2 RBD second dose secretion seroconversion rate seropositive significantly higher status Stimulation T cells the cells the receptor-binding domain understanding vaccination vaccination schedule Vaccination strategy Vaccine [DOI] 10.1128/mbio.00181-22 PMC 바로가기 [Article Type] Article
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRandomized Controlled Trial Published on 2022-06-092022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 유전자 메커니즘, 임상, 진단, [키워드] 95% CI addition Adjusted analysis anti-SARS-CoV-2 anti-Spike IgG Antibody Response assigned AstraZeneca baseline benefit BNT162b2 booster Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 Cohort COVID-19 vaccine dose Effect eight EudraCT Evidence Exploratory analyses exploratory analysis finding funding Future geometric mean concentration geometric mean ratio group groups Heterologous heterologous vaccine homologous humoral humoral immunogenicity immune persistence immune response immunogenic Immunogenicity analysis Immunological response intention-to-treat interval intervals ISRCTN ITT ITT analysis less Older participant persistence Pfizer/BioNTech platform priming randomised Randomly reactogenic reactogenicity reduced Registered SARS-COV-2 infection second dose significant difference significantly higher spike IgG study groups Support T-cell Response the vaccine titre Trial Vaccine Virus neutralisation [DOI] 10.1016/S2213-2600(22)00163-1 [Article Type] Randomized Controlled Trial
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials건강한 성인에서 코로나백 3차 접종의 면역원성 및 안전성, 2회 접종 일정의 면역 지속성: 2건의 단일 센터, 이중 맹검, 무작위, 위약 대조 임상 2상 임상 시험의 중간 결과Clinical Trial Published on 2022-04-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 1:1 95% CI Abstract Administered Adverse reaction analysed antibody Antibody titre assigned Beijing booster dose China clinical trial clinical trials Cohort cohorts Concentration CoronaVac country Cutoff declined development dose doses double-blind eligible foundation GenBank accession number generate geometric geometric mean titre GMIs GMT GMTs groups healthy immune memory immune persistence immune response immunogenicity Inactivated vaccine increase increase in injection Jiangsu material natural neutralising antibody neutralising antibody titre Older outcome participant per-protocol population phase 2 trial Placebo placebo group placebo-controlled positive Program protocol amendment randomised Randomly recalled receive Registered reported resulting SARS-CoV-2 Science second dose Serious Adverse Event seropositive severity significantly increased technology threshold translation Trial vaccination vaccination against COVID-19 vaccination schedule Vaccine virus strain [DOI] 10.1016/S1473-3099(21)00681-2 PMC 바로가기 [Article Type] Clinical Trial
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial청소년 및 노인의 SARS-COV-2 재조합 스파이크 단백질 백신 (NVX-COV2373)의 상이한 용량 요법 : 2 상 무작위 위약 대조 시험Clinical Trial Published on 2021-10-012022-08-13 Journal: PLoS Medicine [Category] Biochemistry, MERS, SARS, 임상, 진단, [키워드] 95% CI 95% confidence interval accumulate addition Administered Adults adverse events age Anti-spike Antibody Response assessments assigned composed conducted convalescent sera coronavirus Day dose dose regimen Efficacy Endpoint Enrollment exceeded Follow-up Formica Frequency full-length SARS-CoV-2 geometric mean geometric mean titer geometric mean titers GMTs group groups identify IgG immune persistence immune response immune responses immunogenic immunogenicity Immunoglobulin Immunoglobulin G include inhibitory concentration intensity intramuscular dose lack limitation Matrix-M1 adjuvant median Mild mild to moderate moderate neutralizing antibody Neutralizing antibody response neutralizing antibody responses NVX-CoV2373 occurred less Older Older adults participant Participants Phase 1 Phase 2 Placebo placebo-controlled placebo-controlled trial primary endpoints Protein Randomized randomized placebo-controlled trial Randomly reactogenicity receive Recombinant spike protein regimen researcher respiratory Respiratory Coronavirus robust safety follow-up SARS-CoV-2 second dose second vaccination secondary endpoint seroconversion rate seroconversion rates severity short duration spike glycoprotein spike glycoproteins Spike protein Support The United States These data Tolerability Treatment Trial Trial registration trimeric United States USA vaccination Vaccine vaccine group wild-type virus [DOI] 10.1371/journal.pmed.1003769 PMC 바로가기 [Article Type] Clinical Trial
[Analysis of the development trend and severity of the COVID-19 panidemic in the global world][전 세계 코로나19 범유행의 발전 추세 및 심각성 분석]Article Published on 2021-06-182022-09-11 Journal: Beijing da xue xue bao. Yi xue ban = Journal of Pe [Category] SARS, 변종, [키워드] affected Asia Brazil Chinese confirmed case confirmed cases coronavirus country COVID-19 cumulative development Development trend distribution Effectiveness English Epidemic Epidemics equity Europe exceeded feasible Focusing France Genotype Germany Global greater help higher risk immune persistence IMPROVE incidence incidence density India Italy mutant mutate National North America novel Novel coronavirus premise repeated Research research and development risk Russia severity severity of COVID-19 Severity. South Africa South America Spain the epidemic The United States the vaccine United Kingdom United States vaccinate vaccination rate Vaccine Vaccines Variation virus [DOI] 10.19723/j.issn.1671-167X.2021.03.016 PMC 바로가기 [Article Type] Article
Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal modelsResearch Article Published on 2020-12-102022-10-31 Journal: Emerging Microbes & Infections [Category] COVID-19, SARS, [키워드] adjuvants Analysis animal model animal models biochemical analysis Biological characterized clinical trial confirmed case COVID-19 COVID-19 pandemic demonstrated develop DNase effective intervention effective vaccine Health humoral immune response IgG immune persistence immunization immunogenicity inactivated Inactivated vaccine investigated limit Neutralizing antibodies observation performed Phase I preclinical data preclinical study product proportion PROTECT reported Safe SARS-CoV-2 Seroconversion Seven shown Side effects Spread stimulated structural protein tested the disease the vaccine Toxicity Vaccine vaccine candidate virion Virology virus WHO Wuhan [DOI] 10.1080/22221751.2020.1852059 PMC 바로가기 [Article Type] Research Article